Understanding participation in recurrent ovarian cancer treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how patients with ovarian cancer that has come back participate in treatment decisions. It may help improve care for others in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with ovarian cancer that has come back
- You can understand the study and give your permission
- You are able to fill out electronic reports
- You can sign and return a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a targeted treatment, chosen based on tumor biology, can help people with recurrent ovarian cancer. You may be asked to give a tumor biopsy so researchers can analyze specific “signal” activity in your cancer.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new combination of drugs for ovarian cancer that has come back after responding to platinum chemotherapy. The goal is to see if adding these drugs helps control the cancer longer.
This study tests if personalized treatment plans, based on detailed genetic testing of your tumor, can help women with recurrent ovarian, cervical, or endometrial cancer. You will work with a team of specialists to find the best options for you.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.